» Articles » PMID: 8675681

Hereditary Hepatic and Systemic Amyloidosis Caused by a New Deletion/insertion Mutation in the Apolipoprotein AI Gene

Overview
Journal J Clin Invest
Specialty General Medicine
Date 1996 Jun 15
PMID 8675681
Citations 19
Authors
Affiliations
Soon will be listed here.
Abstract

We report a Spanish family with autosomal-dominant non-neuropathic hereditary amyloidosis with a unique hepatic presentation and death from liver failure, usually by the sixth decade. The disease is caused by a previously unreported deletion/insertion mutation in exon 4 of the apolipoprotein AI (apoAI) gene encoding loss of residues 60-71 of normal mature apoAI and insertion at that position of two new residues, ValThr. Affected individuals are heterozygous for this mutation and have both normal apoAI and variant molecules bearing one extra positive charge, as predicted from the DNA sequence. The amyloid fibrils are composed exclusively of NH2-terminal fragments of the variant, ending mainly at positions corresponding to residues 83 and 92 in the mature wild-type sequence. Amyloid fibrils derived from the other three known amyloidogenic apoAI variants are also composed of similar NH2-terminal fragments. All known amyloidogenic apoAI variants carry one extra positive charge in this region, suggesting that it may be responsible for their enhanced amyloidogenicity. In addition to causing a new phenotype, this is the first deletion mutation to be described in association with hereditary amyloidosis and it significantly extends the value of the apoAI model for investigation of molecular mechanisms of amyloid fibrillogenesis.

Citing Articles

Amyloidogenic 60-71 deletion/ValThr insertion mutation of apolipoprotein A-I generates a new aggregation-prone segment that promotes nucleation through entropic effects.

Namba N, Ohgita T, Tamagaki-Asahina H, Nishitsuji K, Shimanouchi T, Sato T Sci Rep. 2023; 13(1):18514.

PMID: 37898709 PMC: 10613298. DOI: 10.1038/s41598-023-45803-y.


A new genetic variant of hereditary apolipoprotein A-I amyloidosis: a case-report followed by discussion of diagnostic challenges and therapeutic options.

Moutafi M, Ziogas D, Michopoulos S, Bagratuni T, Vasileiou V, Verga L BMC Med Genet. 2019; 20(1):23.

PMID: 30665372 PMC: 6341640. DOI: 10.1186/s12881-019-0755-5.


Renal Amyloidosis Associated With 5 Novel Variants in the Fibrinogen A Alpha Chain Protein.

Rowczenio D, Stensland M, de Souza G, Strom E, Gilbertson J, Taylor G Kidney Int Rep. 2017; 2(3):461-469.

PMID: 29142973 PMC: 5678610. DOI: 10.1016/j.ekir.2016.11.005.


Apolipoprotein A-1-related amyloidosis 2 case reports and review of the literature.

Lu C, Zuo K, Lu Y, Liang S, Huang X, Zeng C Medicine (Baltimore). 2017; 96(39):e8148.

PMID: 28953655 PMC: 5626298. DOI: 10.1097/MD.0000000000008148.


Structural Insights into High Density Lipoprotein: Old Models and New Facts.

Gogonea V Front Pharmacol. 2016; 6:318.

PMID: 26793109 PMC: 4709926. DOI: 10.3389/fphar.2015.00318.


References
1.
Nichols W, GREGG R, BREWER Jr H, Benson M . A mutation in apolipoprotein A-I in the Iowa type of familial amyloidotic polyneuropathy. Genomics. 1990; 8(2):318-23. DOI: 10.1016/0888-7543(90)90288-6. View

2.
Vigushin D, Gough J, Allan D, Alguacil A, Penner B, Pettigrew N . Familial nephropathic systemic amyloidosis caused by apolipoprotein AI variant Arg26. Q J Med. 1994; 87(3):149-54. View

3.
Maury C, Kere J, Tolvanen R, de la Chapelle A . Finnish hereditary amyloidosis is caused by a single nucleotide substitution in the gelsolin gene. FEBS Lett. 1990; 276(1-2):75-7. DOI: 10.1016/0014-5793(90)80510-p. View

4.
Nelson S, Lyon M, Gallagher J, Johnson E, Pepys M . Isolation and characterization of the integral glycosaminoglycan constituents of human amyloid A and monoclonal light-chain amyloid fibrils. Biochem J. 1991; 275 ( Pt 1):67-73. PMC: 1150014. DOI: 10.1042/bj2750067. View

5.
Eggerman T, Hoeg J, Meng M, Tombragel A, Bojanovski D, BREWER Jr H . Differential tissue-specific expression of human apoA-I and apoA-II. J Lipid Res. 1991; 32(5):821-8. View